Literature DB >> 3665114

Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level.

J Geller1, J Liu, J Albert, W Fay, C C Berry, P Weis.   

Abstract

To evaluate the role of small amounts of prostatic tissue dihydrotestosterone (DHT) as a stimulus to epithelial cell protein synthesis, we studied tissue from 27 patients given various androgen-blocking drugs for 1 week before transurethral resection of the prostate (TURP) and measured epithelial protein synthesis and DHT levels in the tissue specimens. Test drugs before TURP included megestrol acetate 160 mg per day, with and without Tamoxifen 40 mg per day, or ketoconazole 1200 mg per day. The tissue was processed immediately and epithelial cells separated by digestion of tissue with 0.5% collagenase. After separation, epithelial cells were labelled with either 3H-leucine or L-35S-methionine. The DHT level was measured in whole prostatic tissue. Megestrol acetate alone and with tamoxifen significantly decreased both the incorporation of 3H-leucine into protein and the tissue concentration of DHT; megestrol acetate plus ketoconazole significantly decreased L-35S-methionine incorporation into protein and the DHT level. When the data correlating DHT with protein synthesis using both labelling techniques were combined, the curves were parallel and a strong correlation was noted between DHT and protein synthesis over a wide range of values (P less than 0.001). These results suggest that in hormone-dependent prostatic cancer even small amounts of prostatic DHT such as may occur from adrenal androgens following castration may significantly stimulate protein synthesis of the tumour epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665114     DOI: 10.1111/j.1365-2265.1987.tb00771.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

Review 1.  Review of assessment of total androgen blockade as treatment of metastatic prostate cancer.

Authors:  J Geller
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

Review 2.  New hormonal therapies for castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel; Stephen Plymate
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-14       Impact factor: 4.741

3.  Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.

Authors:  Eleni Efstathiou; Mark Titus; Sijin Wen; Patricia Troncoso; Anh Hoang; Paul Corn; Ina Prokhorova; John Araujo; Carl Dmuchowski; Amal Melhem-Bertrandt; Shiva Patil; Christopher J Logothetis
Journal:  Eur Urol Oncol       Date:  2019-04-20

Review 4.  Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.

Authors:  Srinivas Nandana; Leland Wk Chung
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

Review 5.  Practical guide to the use of abiraterone in castration resistant prostate cancer.

Authors:  Elahe A Mostaghel; Daniel W Lin
Journal:  Can J Urol       Date:  2014-04       Impact factor: 1.344

Review 6.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.

Authors:  Elahe A Mostaghel; Peter S Nelson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

7.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors:  R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

Review 8.  Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.

Authors:  Elahe A Mostaghel; Bruce Montgomery; Peter S Nelson
Journal:  Urol Oncol       Date:  2009 May-Jun       Impact factor: 3.498

Review 9.  Abiraterone in the treatment of metastatic castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Cancer Manag Res       Date:  2014-01-28       Impact factor: 3.989

10.  Steroid hormone synthetic pathways in prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Transl Androl Urol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.